Literature DB >> 15213841

Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells.

Sven Becker1, Jeremy C Simpson, Rainer Pepperkok, Stefan Heinz, Christian Herder, Manuel Grez, Erhard Seifried, Torsten Tonn.   

Abstract

In mammalian cells, factor VIII (FVIII) secretion depends upon its interaction with chaperones of the endoplasmic reticulum (ER) and requires a unique ATP-dependent step to dissociate aggregates formed within the ER. To further elucidate mechanisms which might account for the inefficient secretion of recombinant FVIII (rFVIII), we have analyzed the pathways of recombinant full length (rFVIII-FL) and B-domain deleted (rFVIII Delta B) FVIII and compared these to the secretion route of native FVIII in primary hepatocytes. Using confocal laser scanning microscopy in combination with a pulse chase of a known secretion marker, we describe the trafficking route of FVIII, which upon release from the ER--where it colocalizes with calnexin--is transported to the Golgi complex in vesicular-tubular transport complexes (VTCs) which could be further identified as being COP I coated. However, a large portion of rFVIII is retained in the ER and additionally in structures which could not be assigned to the ER, Golgi complex or intermediate compartment. Moderate BiP transcription levels indicate that this observed retention of FVIII does not reflect cellular stress due to an overexpression of FVIII-protein in transduced cells. Moreover, a pulse of newly synthesized rFVIII protein is released within 4 hrs, indicating that once rFVIII is released from the ER there is no further limitation to its secretion. Our data provide new details about the secretory route of FVIII, which may ultimately help to identify factors currently limiting the efficient and physiological expression of FVIII in gene therapy and manufacture.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15213841     DOI: 10.1160/TH03-06-0360

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  13 in total

1.  Expression of human coagulation factor VIII in a human hybrid cell line, HKB11.

Authors:  Baisong Mei; Yaoqi Chen; Jianmin Chen; Clark Q Pan; John E Murphy
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.695

2.  Advancements in gene transfer-based therapy for hemophilia A.

Authors:  Christopher B Doering; H Trent Spencer
Journal:  Expert Rev Hematol       Date:  2009-12       Impact factor: 2.929

Review 3.  Production of recombinant coagulation factors: Are humans the best host cells?

Authors:  Kamilla Swiech; Virgínia Picanço-Castro; Dimas Tadeu Covas
Journal:  Bioengineered       Date:  2017-02-23       Impact factor: 3.269

4.  Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein.

Authors:  Ryan J Summers; Shannon L Meeks; John F Healey; Harrison C Brown; Ernest T Parker; Christine L Kempton; Christopher B Doering; Pete Lollar
Journal:  Blood       Date:  2011-01-07       Impact factor: 22.113

5.  Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.

Authors:  Lindsey A George; Paul E Monahan; M Elaine Eyster; Spencer K Sullivan; Margaret V Ragni; Stacy E Croteau; John E J Rasko; Michael Recht; Benjamin J Samelson-Jones; Amy MacDougall; Kristen Jaworski; Robert Noble; Marla Curran; Klaudia Kuranda; Federico Mingozzi; Tiffany Chang; Kathleen Z Reape; Xavier M Anguela; Katherine A High
Journal:  N Engl J Med       Date:  2021-11-18       Impact factor: 91.245

6.  Endothelial cell processing and alternatively spliced transcripts of factor VIII: potential implications for coagulation cascades and pulmonary hypertension.

Authors:  Claire L Shovlin; Gillian Angus; Richard A Manning; Grace N Okoli; Fatima S Govani; Kay Elderfield; Graeme M Birdsey; Inês G Mollet; Michael A Laffan; Francesco A Mauri
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

Review 7.  Gene therapy for hemophilia.

Authors:  Geoffrey L Rogers; Roland W Herzog
Journal:  Front Biosci (Landmark Ed)       Date:  2015-01-01

8.  Chemical chaperones improve protein secretion and rescue mutant factor VIII in mice with hemophilia A.

Authors:  Stefanie D Roth; Jörg Schüttrumpf; Peter Milanov; Daniela Abriss; Christopher Ungerer; Patricia Quade-Lyssy; Jeremy C Simpson; Rainer Pepperkok; Erhard Seifried; Torsten Tonn
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

9.  Quantitative correlation between transcriptional levels of ER chaperone, peroximal protein and FVIII productivity in human Hek-293 cell line.

Authors:  Evandra Strazza Rodrigues; Virgínia Picanço-Castro; Marta Regina Espanhol; Luiz Alberto Martins de Andrade; Patricia Vianna Bonini Palma; Simone Kashima; Aparecida Maria Fontes; Dimas Tadeu Covas
Journal:  Springerplus       Date:  2013-07-18

10.  Comparison of human coagulation factor VIII expression directed by cytomegalovirus and mammary gland-specific promoters in HC11 cells and transgenic mice.

Authors:  Qing Wang; Siguo Hao; Liyuan Ma; Wenhao Zhang; Jiangbo Wan; Xiaohui Deng
Journal:  Blood Coagul Fibrinolysis       Date:  2015-10       Impact factor: 1.276

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.